et al.. Sensitization of EGFR wild-type non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitor erlotinib.: wtEGFR non-small cell lung cancer sensitization to erlotinib. Molecular Cancer Therapeutics, American Association for Cancer Research, 2017, 16 (8) transactivating EGFR through a ligand-independent activation. We propose a combination of markers which enable to discriminate between the tumors sensitized to erlotinib or not in PDX models, that should be worth testing in patients.These markers might be useful for the selection of patients who would benefit from erlotinib as a maintenance therapy.
Introduction
EGFR is the receptor for epidermal growth factor (EGF) and belongs to the tyrosine kinase receptors (RTK).This transmembrane receptor protein is involved in the fine regulation of epithelial cells proliferation through the extracellular binding of its ligands and the complex cross-talk with several membrane receptors, including the other members of the erbB/HER-family (1) . The very subtle regulation is achieved by the multiplicity and redundancy of the ligands and dimerization partners of EGFR (1, 2) . The broad field of its downstream signaling pathways also stands for the multiplicity of biological effects induced by EGFR activation (3) . Several reports besides revealed a non-canonical, ligand-independent activation (trans-activation) of EGFR(4) in epithelial and nonepithelial cells (5, 6) . This points out that the biological role of EGFR oversteps the sole regulation of cell proliferation in response to EGF-like ligands.
EGFR mutation is one of the major driver mutations in non-small cell lung cancer (NSCLC).EGFR tyrosine kinase inhibitors (EGFR-TKI) have constituted a significant advance in the care of patients which tumors harbour a mutated, activated form of EGFR (7) . Conversely, the indication of EGFR-TKI in patients with wtEGFR tumor is more debated (8) (9) (10) . If the absence of efficacy is demonstrated in first-line treatment, pretreated patients could benefit from EGFR-TKI.Aside from the newly arising immune-based therapies, targeted therapies are of high efficiency in the case of oncogenic mutation-driven tumors, even only a small percentage of tumors are concerned so far.
Despite much effort was made in order to find out new therapeutic strategies in lung cancer, platinum-based chemotherapy (associated to pemetrexed) remains the backbone therapy in wildtype EGFR non-small cell lung cancer (NSCLC).
The first-line chemotherapy induces drastic modifications of cancer cells, at the nongenetic (11) or genetic levels (12) . Such events are susceptible to alter the cell response to the subsequent treatments and underline the need for repeated biopsies along the treatment (13) . This can account for the observations made in clinical trials that wild-type EGFR patients benefit from cisplatin treatment was shown to induce EGFR activation in lung cancer cell lines (14) . Given the fact that cisplatin is the usual first-line chemotherapy for wild-type EGFR NSCLC, we aimed at investigating the consequences of a sublethal cisplatin treatment upon the surviving cells sensitivity to erlotinib, either in wild-type or mutated-EGFR cell lines. We also questioned the effect of longterm cisplatin exposure to sensitized cells and explored the molecular pathways involved. We finally used lung cancer patients derived xenografts (PDX) to challenge the sensitization observed in vitro and found out markers of the described sensitization, thereby bringing a new perspective to the use of EGFR-TKI in EGFR wild-type NSCLC.
Materials and methods
Material used wtEGFR (A549, H358 and H522) and mutant EGFR cell lines (H1650 and H1975) were purchased from the ATCCbetween 2011 and 2012. Cells from an individual frozen stock vial were grown for a maximum of four consecutive months and were monthly tested for Mycoplasma contamination.
They were grown and treated by the indicated drugs in 10% fetal bovine serum-containing medium (RPMI 1640, Gibco, ThermoFischer Scientific) unless otherwise stated. The references of the antibodies used were following: membrane EGFR, Santa Cruz #sc-120; membrane Her2, Santa Cruz #sc-23864; membrane Her3, Santa Cruz #sc-71068; phospho-EGFR (Y1068), Cell Signaling Technology #3777; phospho-AKT (S473), Cell Signaling Technology #9271; phospho-ERK1/2 (T202/Y204), Cell Signaling Technology #9101; total EGFR, Cell Signaling Technology #4267; GRB2, BD Biosciences #610112; pTyr100, Cell Signaling Technology #9411; blocking EGFR antibody (225), Invitrogen #MA5-12880; blocking IL6 antibody, R&D Systems #MAB206; control IgG1, RnD Systems #MAB002. PP1 and PP2 inhibitors (15) were purchased from Sigma Aldrich (#P0040 and #P0042). ELISA kits were purchased from R&D Systems and used according to the manufacturer's instructions.
All experiments were repeated three times independently unless otherwise stated and analyzed by Student t-test. 
Conditioned medium preparation
Cells were plated in 100mm-dishes and treated by cisplatin (3µM, 48h). Cells were then rinsed and culture medium was replaced by fresh serum-free medium. After 48h, cell supernatant was centrifuged to remove cells fragments and used for the described experiments. Cells were trypsinised and counted to normalize ligand measurements by the cell number.
Proximity Ligation Assay (PLA) Cells were seeded in 24-well plates onto glass sterile coverslips and allowed to attach overnight. The indicated treatment was applied, then cells were fixed by 4% paraformaldehyde. The labeling with antibodies was realized according to the PLA manufacturer instructions (Duolink, Sigma-Aldrich).
Image acquisition was performed with a Zeiss Apotome microscope (Zeiss Axiovert 200-M inverted microscope and AxioVision 4.6 program, Carl Zeiss Gbmh). Data were analyzed by the ImageJ 1.46r software and spots were quantified by the Object 3D Counter plugin.
IC50 measurements
IC50 measurements were calculated according to Chou et al.(16) by the MTT method. Briefly, cells were plated in 96-well plates (5000 cells/well) and treated by the indicated drugs or conditioned media. Cells were incubated with MTT 3h at 37°C, formazan cristae were solubilized in DMSO and optical density (OD) was read at 570nm.
Preclinical PDX models
Four to six week-old Nude mice, bred at Institut Curie, were used. Tumor fragments of 30-50mm 3 were grafted subcutaneously into the interscapular fat pad. When tumors reached a size of about 50- 
RT and qPCR
Total RNA was isolated from cell pellets or from frozen PDX pieces using the RNeasy MiniKit (Qiagen) following the manufacturer's instructions with DNase I treatment. After RNA quantification by spectrophotometry (BioSpectrometer, Eppendorf, France), 1µg RNA was reverse-transcribed with Quantiscript Reverse Transcriptase (Qiagen, France) for cDNA synthesis. Quantitative real-time PCR assays were performed and monitored in technical duplicate using a Rotor-Gene Q PCR system (Qiagen, France). Data were normalised by three housekeeping genes (RPLP0, Actin and GAPDH)and expressed as fold change versus control conditions (non-treated cells or control mice). Primers used were purchased from Qiagen and validated by the supplier (QuantiTect primers : IFIT1 QT00201012, IFI27 QT00099274, IL6 QT00083720, RPLP0 QT00075012, Actin QT01680476, GAPDH QT00079247).
PCA analysis PCA analysis (Pearson's correlation) was performed from the data described in Table S1 using XLSTAT v2016.03 software (Addinsoft 2010).
Results
Cisplatin primes EGFR wild-type cells toerlotinib through the activation of EGFR pathway.
We worked with three EGFR wild-type (wtEGFR) cell lines (namely A549, H358 and H522) and with two mutant EGFR (mutEGFR) cell lines (H1650 and H1975, respectively exhibiting A746-A750 deletion and L858R-T790M mutations). We first measured the membrane expression of EGFR, Her2 and Her3 in the different cell lines ( figure 1A) . Most of the cell lines significantly expressed EGFR, except from Cisplatin treatment thus induced a priming event to the subsequent erlotinib treatment. Smith et al.(20) established a correlation between EGFR-GRB2 complexes detection and the response to EGFR inhibitors. We actually confirmed that cisplatin pretreatment significantly up-regulated the amount of EGFR-GRB2 interactions detected by the PLA technique in wtEGFR cells (figure 1D and S2-E).
EGFR is activated in cisplatin-resistant cells.
We generated a cisplatin-resistant cell line derivated from A549 cells by constant exposure to 3µM cisplatin. After a few weeks, cells began to proliferate and could be passaged and subcultured in the presence of cisplatin. We objectified the resistance to cisplatin of these cells, named A549cis3 EGFR is classically activated through the binding of its ligands and consequent dimerization responsible for its autophosphorylation. We first challenged the ability of cisplatin-treated cells to increase the sensibility of wtEGFR naive cells to erlotinib. We prepared conditioned media (CM) from A549 cells either treated by cisplatin (3µM, 48h) or not and from the resistant A549cis3 cells. Naive A549 cells were incubated overnight with the conditioned media and then treated by erlotinib. The conditioned media from cisplatin-treated and cisplatin-resistant cells decreased the cells resistance to erlotinib (figure 3A), indicating that a secreted factor is implicated in the cisplatin-induced sensitization to erlotinib. To objectify EGFR activation, we measured EGFR phosphorylation by theDuolink technique. We actually observed that cisplatin-treated cells secrete a soluble factor responsible for EGFR phosphorylation (figure 3B). We measured the secretion of EGFR ligands and of some known regulators of EGFR activation (namely PGE2 and HGF)by cisplatin-treatedwtEGFR cells.Amphiregulin secretion was increased by cisplatin treatment in all the tested cell lines ( figure   3C , left graph). TGF secretion was induced in two cell lines except from the A549 cells (figure 3C, middle graph) while PGE2 secretion was only induced in A549 conditioned medium (figure 3C, right graph). We made several attempts to establish the role of these secreted molecules in the sensitization to erlotinib observed. As cisplatin-treated A549 CM could sensitize A549 cells to erlotinib, we treated naive A549 cells with recombinant amphiregulin, PGE2 or the combination of both, at the concentrations measured in the conditioned media, but the sensitivity of the treated cells to erlotinib was not modified (figure S3-A).We tested the ability of various CM obtained from control and cisplatin-treated cell lines to sensitize A549 cells to erlotinib related to the evolution of the same EGFR regulators concentrations as in figure 3C . As summarized in figure 3D , these experiments could not shed the light on any regulator or combination of regulators. In order to conclude on the direct activation of EGFR by a secreted molecule induced by cisplatin, we questioned the sensitivity of the naive and cisplatin-treated wtEGFR cells to a blocking EGFR antibody (analog to the anti-EGFR drug cetuximab). As indicated in figure 3E and supplementary figure S3 Cisplatin injection can sensitize wtEGFR patients-derivated xenografts to erlotinibin vivo.
We next investigated the capacity of cisplatin initial treatment to enhance the response of wtEGFRtumors to erlotinibin vivo. We used a set of four PDXs (patient-derived xenografts) (LCF-04, LCF-09, IC14-LC16 and IC8-LC10), obtained from human non-small cell lung cancer (NSCLC) pieces xenografted to Swiss Nude mice. The use of PDXs for preclinical studies was shown to better reflect the phenotype and heterogeneity of human lung cancer tumors than cell lines xenografts (23) (24) (25) .The histological type of PDX was confirmed and compared to the initial tumors. Tumors were classified as adenocarcinomas and expressed wild-type EGFR, KRAS, BRAF and PI3K. Mice were randomly assigned to four groups since tumors reached an initial volume ranged between 50 and 100mm 3 . The "control" group received no treatment; the "cisplatin" group received an intraperitoneal injection of cisplatin at day 1 (6mg/kg); the "erlotinib" group was orally treated by erlotinib(50mg/kg) 5 days out of 7 from day 7 to the mice sacrifice; the "cisplatin/erlotinib" group was treated by both drugs as described above. Tumor growth was measured twice a week and represented on the graphs in figure   5 as mean relative tumor volume in each group +/-SD. In comparison to each monotherapy, i.e. cisplatin or erlotinib, tumor growth was significantly inhibited by the sequential treatment in three out of four models with variable efficiency, whereas no benefit was observed in tumor D (IC8-LC10) either at early or late time points.Of note, when tumors were allowed to grow for a longer time (figure S5), the initial sensitization to erlotinib tended to disappear in two PDX models.Differences are observed in tumor growth rates and response to each drug or drug combination, which is consistent with the heterogeneity of lung tumors phenotype. These results suggest that cisplatin may actually enhance the response of some human NSCLC tumors to erlotinibin vivo and require the identification of these tumors by the definition of a predictive marker.
IL6, IFIT1 and IFI27 measurement can discriminate between responding and non-respondingwtEGFR tumors.
We have demonstrated the role played by IL6 in the ligand-independent activation of EGFR induced by cisplatin. Ligand-independent activation of EGFR is correlated to IFIT1 and IFI27 transcription in glioma (26) . We therefore measured the expression induction of IL6, IFIT1 and IFI27 in cisplatintreated (A549 + cisp) and cisplatin-resistant (A549cis3) A549 cells. The transcription of all three markers was increased in cisplatin-treated and cisplatin-resistant cells (figure 6A), in a timedependent manner for the short-term treatment ( figure S6-A) . These three potential markers were challenged for their fitting to the sensitization of wtEGFRtumors to erlotinibin vivo by the use of the PDX models described above. PDXs A, B and D (figure 5) were grafted to Swiss Nude mice. Mice were treated by cisplatin at day 1 after randomization. Mice were sacrificed at day 4, 8 and 18and tumors were excised and frozen. A group of control, non-treated mice was sacrificed at day 4.mRNA were extracted from the tumors and analyzed for the expression of IL6, IFIT1 and IFI27. Figure 6B figure 6C and figure S6, these markers could discriminate between responding and non-responding PDXs. The time point day-8 seems to divert from the other time points. We therefore repeated the same PCA with the measurement made from the PDXs at day-8 and the analysis efficiently discriminated between responding and non-responding PDXs (figure S6-B) (98.37%). As described in figure S7 , at day 8, only tumors from the PDX D group can be found in the Treatment-NT confidence ellipse, whereas responding tumors significantly diverge from this ellipse at day 8.
Discussion
The aim of our study was to increase understanding of the modifications induced in NSLCL cells by a cisplatin sublethal treatment towards EGFR pathway. We provide here evidence of a ligandindependent, Src-mediated activation of EGFR induced by cisplatin treatment in NSCLC cells expressing wild-type EGFR. This activation results in a sensitization of wtEGFR cells to erlotinib, an EGFR-TKI.This increase in erlotinib efficiency is reproduced in vivo in PDX models, which is reported for the first time to our knowledge. Some previous reports have shown the ability of chemotherapy, including cisplatin, to induce EGFR activation, in several cell types (14, (27) (28) (29) but the functional consequences regarding the cells sensitivity to EGFR inhibition are less clear. Surprisingly, depending on the model considered, EGFR activation either promoted cell survival and tumor growth (14) or sometimes cell death (27) . This activation sometimes functionally came out as an increased sensitivity to EGFR inhibitors, either EGFR-TKI or EGFR blocking antibody (29), sometimes not (19) .
The signaling pathways leading to EGFR activation as well as pathways activated by EGFR phosphorylation are extremely various. These many signaling options could explain thediscrepancies between in vitro or clinical reports studying the interplay between chemotherapy and EGFR inhibition. The sequence of events we describe here, leading to the increase in erlotinib efficiency, may be specific from platinum-based priming. This will be the subject of further investigation.
The observations we report here are in agreement with the conclusions of the clinical study SATURN that established the benefit of erlotinib as maintenance therapy in patients with EGFRpositive NSCLC after four cycles of platinum-doublet chemotherapy (8) . A more recent study reevaluated the results of the SATURN and BR.21 trials with a focus on wtEGFR patients and confirmed the benefit of erlotinibafter initial platinum doublet therapy in these patients (30) .Recently, the IUNO clinical trial comparing the benefit of erlotinib as maintenance treatment versus as second line therapy in wtEGFR patients failed at demonstrating any benefit of erlotinib in the cohort with either therapeutic schedule (31) .Clinical studies suggest that erlotinib maintenance could be more efficient in tumor controlled by the initial platinum-based therapy (32) .We have established that cisplatin-resistant cells, arisen from constant exposure of sensible cells to cisplatin, exhibited the same pattern of EGFR activation and erlotinib sensitivity as short-term treated cells.
This suggests that some patients could benefit from erlotinib maintenance even if tumor escapes from platinum-based chemotherapy, providing the markers of sensitization are expressed. The increased sensitivity of chemotherapy-resistant cells to EGFRinhibition has also been observed in other cell types, suggesting that this sensitization may not solely interest lung cancer cells and cisplatin (28) . Of note, Rho et al. observed that the generation of cisplatin-resistant cells by discontinued exposure of cells to increasing concentration followed by drug vacancy did not alter the cells sensitivity to EGFR-TKIs (33) . This is consistent with our findings that erlotinib must be given short after cisplatin treatment, whatever the duration of cisplatin exposure. The observations made in our PDX models also suggest that erlotinib benefit is maximal at early time after cisplatin treatment. Repeated cisplatin injections may be of interest to restore erlotinib sensitization when tumor escape happens and could be assayed. This hypothesis is substantiated by a very recent metaanalysis of randomized clinical trials suggesting that the addition of intercalated EGFR-TKI to chemotherapy could be of interest in NSCLC (34) . An in vitro study demonstrated however that EGFR-TKI tolerance results from reversible, epigenetic cell phenotype modifications (11) . These modifications also result in a decreased sensitivity to cisplatin, suggesting that erlotinib-resistant tumors should be either submitted to a transient drug vacancy or to an HDAC inhibitor before cisplatin should be repeated. All together, these studies further reinforce the need of markers to identify the tumors susceptible to respond to EGFR-TKI and the optimal moment when they should be introduced in the therapeutic schedule.
This point, namely the utmost importance of the kinetics of the therapeutic schedule, underlines the major difference between the epigenetic, inheritable mechanism of EGFR-TKI tolerance described by Sharma et al.(11) and the mechanism of cisplatin resistance observed in our model, the former rendering the cells resistant to cisplatin and the latter rendering the cells sensitive to EGFR-TKI by the activation of a specific pathway. The results we report herecompared to those reported by Sharma et al.(11) point out the importance of the sequence of cisplatin and erlotinib therapies. The initial cisplatin treatment is required for EGFR activation prior to erlotinib introduction, whereas initial EGFR-TKI treatment might favor the resistance of surviving cells to cisplatin. The observation that erlotinib combination with concurrent cisplatin showed no clinical benefit (9) also corroborates our in vitro data and the requirement of the sequential treatment. It also became quite clear, both invitro and in vivo, that EGFR inhibition impairs the efficiency of chemotherapy when administrated first (35) . Tumor cells drastically evolve from the initial biopsybased analyses to the therapy-modified phenotype at the time of maintenance, underlining the needforphenotypic reevaluationafter the first-line therapy to optimize the therapeutic strategy (13) .What we show here is that the initial cisplatin treatment induces a cell phenotype modification, linked to Src-dependent and ligand-independent EGFR activation. In this modified cells, EGFR tyrosine kinase function is required to cell survival, since erlotinib then induces cell death. Similar to what was demonstrated in glioblastoma (26) , we show here that cisplatin pretreatment in NSCLC simultaneously renders the cells more sensitive to EGFR-TKI and more resistant to EGFR blocking antibody. It is thus of high importance to consider that EGFR-TKI and EGFR blocking antibody are not redundant and substitutable therapeutic strategies. The former should predominantly target ligand-independent EGFR signaling whereas the latter should only inhibit the ligand-induced signaling. Combining both EGFR targeting strategies may thus enhance tumor response in some models. Some fruitful attempts were reportedin vitro in several models (39) (40) (41) or in clinical trials in lung cancer (42) or in colorectal cancer (43) .
Finally, it is noteworthy that both cell lines sensitized to erlotinib by cisplatin we used in this study express mutated KRAS, whereas all the PDX models we worked with express wild-type KRAS. In the SATURN cohort of patients, KRAS mutation was a significant prognostic factor for poor response to erlotinib (44) .KRAS nevertheless does not appear as a major determinant for the mechanism we describe. This KRAS-independent signaling induced by cisplatin pretreatment is consistent with the activation of ligand-independent EGFR pathway, rather implicating TBK1-IRF3 complex (4). A549 cells express G12S-KRAS and H358 cells express G12C-KRAS. Singh et al.(45) have established that A549 cells were independent from KRAS for their survival, since KRAS knock-down had no impact on cell growth or on downstream kinases (ERK and AKT) phosphorylation. Besides, the constitutive activation of downstream effectors ERK and AKT by G12C-KRAS was the same as wild-type KRAS (46) .
The regulation of ERK and AKT phosphorylation in our KRAS mutated cell lines would thus not involve KRAS. The activation induced by cisplatin might rather be the consequence of Src activation. KRAS mutation should therefore not be an absolute exclusion criterion for EGFR-TKI therapy, in case of ligand-independent activation of EGFR.This suggestion is supported by the observation made in metastatic colon cancer:whereas anti-EGFR antibodies proved to be effective in colorectal cancer excluding the KRAS mutated tumors, the GERCOR DREAM study shows the benefit oferlotinibin maintenance therapy in KRAS mutated colon cancer in combination with angiogenesis inhibition after induction chemotherapy (47).
In conclusion, this work highlights the occurrence of ligand-independent EGFR activation in cisplatin-treated wtEGFR NSCLC. Similar to what happens in glioblastoma, this pathway competes with ligand-induced EGFR signaling (4, 26) , involving plasma membrane EGFR. This could support the fact that some wtEGFR patients may benefit from EGFR-TKI as maintenance therapy when given immediately following to platinum-based therapy. The balance between both activation pathways can account for the reported additive effect of EGFR-TKI and EGFR antibody strategies in some tumors. To achieve this optimization of EGFR-TKI, the validation of ligand-independent EGFR activation markers in NSCLC cohorts is required and will be the subject of further development. A, Conditioned medium (CM) was prepared from A549 cells treated by cisplatin 3µM 48h or not, or from A549cis3 cells. These media were used to dilute erlotinib for the calculation of A549 naïve cells IC50 to erlotinib 72h in CM as described in figure 2(A). **: p<0.01 Student t-test. B, Naïve A549 cells were incubated overnight in the conditioned medium from A549 cells treated by cisplatin 3µM 48h or not. Cells were fixed and incubated with EGFR and pTyr100 antibodies. Phospho-EGFR was detected by PLA and quantified as in figure 1(D) . The graph shown is representative of 5 independent experiments. C, CM was prepared from the three wtEGFR cell lines treated by cisplatin 3µM 48h or not and the indicated compounds were measured by ELISA. Data shown are the mean + SD from 3 independent experiments. **: p<0.01 Student t-test. D, CM were prepared as in C (see material and methods for details); the table summarizes the variation of the indicated compounds concentration in CM and their ability to induce naive A549 cells sensitization to erlotinib. E, A549 cells were treated by cisplatin 3µM 48h or not and then by EGFR blocking antibody 13nM 72h. Cell death was measured by To-Pro3 staining and detected by flow cytometry as in figure 1C . The graph shown is representative of 3 independent experiments.**: p<0.01 Student t-test. Figure 4 : A, A549 cells were treated by the cisplatin -erlotinib (30µM) sequence as described before; when indicated, PP1 (10µM) was added during cisplatin treatment. Cell death was measured by ToPro3 staining and detected by flow cytometry as in figure 1C . The graph shown is representative of 3 independent experiments. **: p<0.01 Student t-test. B, A549 and H1975 cells were treated as in (A) (respectively by erlotinib 30 and 10µM), without (upper graph) or with PP1 (lower graph) added during cisplatin treatment. The graph shown is representative of 3 independent experiments. *: p<0.05 **: p<0.01 Student t-test. C, A549 cells were treated by cisplatin 3µM 48h with PP1 (10µM) added or not. Cells were fixed and stained by pEGFR (pY1068) antibody coupled to a fluorescent secondary antibody and EGFR phosphorylation was detected by flow cytometry. The graph shown is representative of 3 independent experiments. **: p<0.01 Student t-test. D, A549 cells were treated by cisplatin 3µM 48h and IL6 secretion was measured by ELISA in cell supernatants. E, A549 cells were treated as in (A) with IgG or IL6 neutralizing antibody (1µg/ml) added when cisplatin and erlotinib are applied. Cell death was measured by To-Pro3 staining and detected by flow cytometry as in figure 1C . Data shown are the mean + SD from 5 independent experiments. *: p<0.05**: p<0.01 Student t-test. Tumor volume was measured twice a week and normalized to the initial volume. Mean relative volume was calculated for each group and represented on the graphs (+/-SD). Student t-test was realized and significant p values between erlotinib and cisplatin/erlotinib groups were indicated on the graphs, provided that no statistical difference exists between control and cisplatin groups at the same time point.(*: p<0.05 **: p<0.01 Student t-test.) Figure 6 : A, IL6, IFIT1 and IFI27 mRNA expression was measured by RT-PCR in A549 cells treated by cisplatin (3µM, 48h) and in A549cis3 cells and expressed as fold change versus control A549 cells. The graph shows the mean + SD from 3 independent experiments. *: p<0.05 (Student t-test). B: The same mRNA measurements were made in PDX A, B and D at day 4 (A4.1 to 3, B4.1 to 3, D4.1 to 3), 8 (A8.1 to 3, B8.1 to 3, D8.1 to 3) and 18 (A18.1 to 3, B18.1 to 3, D18.1 to 3) post-cisplatin injection and expressed as cumulative fold change versus non-treated PDX (A0.1 to 3, B0.1 to 3, D0.1 to 3). C: A principal component analysis was performed with the mRNA as quantitative variables and with response and time categories as qualitative variables. Table S1 : markers quantification by RT-qPCR in the individual mice.
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